News

The license agreement covers extensive intellectual property rights for AMD-related genetic variants that have been confirmed in multiple clinical studies around the world. The portfolio of intellectual property

Kevin Hrusovsky, president and CEO of Caliper Life Sciences, said: “We have partnered with key thought leaders and customers to create the Sciclone G3 platform, which expands Caliper’s

The official opening ceremony was performed by Friedrich Conzen, major of Dusseldorf. Dr Simon Moroney, chief executive officer of MorphoSys Group, also attended along with Dieter Feger, Head

Reportedly, iCyt plans to develop advanced technologies and deliver new products in collaboration with Sony. Gary Durack will continue to lead the company through this period of growth

The company said that these high-temperature polymers can be used in applications such as respiratory devices, fluid collection containers and others that require optimum strength, chemical resistance and

The agreement to purchase Topigen was announced to the market on 12 January, 2010. An additional 5.0 million shares will be issued subject to the achievement of certain

The company plans to exploit a recently elucidated nasal-cerebral drug delivery route for targeting pain transmission and control pathways in cranial nerves and the CNS, enabling vast new

CPI-300 is a new, high strength of Bupropion HCl, the active ingredient in Wellbutrin XL(R). IntelGenx’s development partner, Cary Pharma, serves as the NDA applicant for CPI-300. The

As per the agreement, AnaptysBio is likely to be responsible for generating new antibodies to a specified disease target, using its proprietary somatic hypermutation (SHM) technology platform. Merck